Relationship Between Visfatin Level and Cardiovascular Changes in Hemodialysis Patients.

Abstract

Background: Cardiovascular alterations include atherosclerosis, calcification, heart failure, diastolic and systolic dysfunction, and stroke are a primary cause of mortality in people with CKD and ESRD. Individuals with CKD have been demonstrated to have increased serum levels of visfatin. A new study suggests that high visfatin levels in individuals with chronic kidney disease accurately predict cardiovascular abnormalities. Chronic renal failure, atherosclerosis, and calcification in the carotid arteries vary in individuals. The researchers set out to look at correlation of visfatin level and cardiovascular abnormalities in CKD patients. In this case-control comparative study, conventional Echocardiogram and carotid duplex assessment were used to evaluate the differences between 40 patients with stage III or stage IV CKD receiving conservative treatment, 40 ESRD patients receiving regular hemodialysis, and 20 subjects as a control group. Results: Hemodialysis-dependent Carotid atherosclerosis, systolic and diastolic dysfunction, and calcifications are more common in ESRD patients compared to non-hemodialysis-dependent individuals that significantly correlated with high serum Visfatin levels compared to healthy control participants. Carotid atherosclerosis, diastolic dysfunction, and systolic dysfunction are all more likely to occur in those with CKD who had increased CIMT p-value (0.036) of carotid doppler, decreased EF % p-value (0.032), increased LVMI p-value (0.004) and reversed E/A ratio p-value (0.003) demonstrated by Echocardiographic and carotid Doppler assessment. Patients with an elevated visfatin level had increased cardiovascular morbidity and mortality and atherosclerosis of the carotid arteries with a high risk of ischemic stroke.